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INTRODUCTION: The use of bone grafts in orthopedic, maxillofacial and dental surgery has been growing. Nevertheless, both 
fresh autografts and frozen allografts have limitations, and therefore, alternative synthetic or natural biomaterials, such as processed 
and lyophilized bovine bone graft have been developed. 
OBJECTIVE: To evaluate in vitro and in vivo biocompatibility of lyophilized bovine bone manufactured in a semi-industrial scale, 
according to a modifical protocol developed by the authors.
METHODS: Samples of bovine cancellous bone were processed according to a protocol developed by Kakiuchi et al., and modi-
fied to process samples of bovine cancellous bone. The following trials were performed: in vitro cytotoxicity, in vivo acute systemic 
toxicity, in vivo oral irritation potential, in vitro pyrogenic reaction, and bioburden.
RESULTS: The in vitro evaluation of lyophilized bovine cancellous bone revealed an absence of cytotoxicity in 100% of the 
samples. Regarding in vivo evaluation of acute systemic toxicity, neither macroscopic abnormalities nor deaths were noted in the 
animals. Pyrogenicity was not greater than 0.125 UE/ml in any of the samples. The bioburden revealed negative results for microbial 
growth before sterilization. Regarding the oral irritation potential, in vivo evaluation at 24 and 72 hours showed that the animals 
had no edema or erythema on the oral mucosa.
CONCLUSION: The protocol changes established by the authors to prepare lyophilized bovine cancellous bone at a semi-industrial 
scale is reproducible and yielded a product with excellent biocompatibility.
KEYWORDS: Surgery; Materials testing; Toxicity tests; Freeze drying; Bone transplantation.
INTRODUCTION
The use of bone grafts in orthopedic, maxillofacial 
and dental surgeries has been growing.1 Fresh autografts 
remain the standard option because of their structural 
properties, absence of immune response, and osteoinductive, 
osteoconductive and osteogenic properties. However, 
disadvantages such as longer surgical times, low availability 
and morbidity have limited their use.2,3 
Frozen allografts have also been widely used and are 
considered an excellent alternative since there is virtually 
no site morbidity, but availability is limited; and, although 
rare, transmission of infectious and tumoral diseases may 
be associated.4-6 
Therefore, alternative synthetic or natural biomaterials 
such as processed and lyophilized bovine bone grafts, as 
well as different bone processing and storage methods, 
have been developed and extensively studied. Bovine grafts 
have almost unlimited availability and great physical and 
chemical similarity to human bone. One of the disadvantages 
of bovine bone is the fact that it is a xenograft and, therefore, 
may trigger unwanted immunological and inflammatory host 
reactions host. Many efforts to develop an optimal protocol 
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have been attempted including physical and chemical 
processing methods to minimize risks and to substantially 
decrease antigenicity, thus rendering bovine bone an 
acceptable alternative to autografts and allografts.7-10 
One of the most important phases in the development 
and biological validation of biodegradable materials is the 
performance of rigorous clinical and experimental in vitro 
and in vivo trials to determine and confirm biocompatibility 
and bioactivity.11-13 
Data obtained in these studies may determine whether the 
material meets the biocompatibility standards for implantable 
medical products. Methods and standards to evaluate the 
biocompatibility of these products are described in the ISO 
10993-11 series of international norms.14 The ISO norms 
have exceeded several attempts and international agreements 
aimed at standardizing the evaluation of medical product 
safety and have been incorporated in several studies.15
This study evaluated the biocompatibility of lyophilized 
bovine bone manufactured in a semi-industrial scale 
according to a novel preparation process developed by the 
authors. The following assessments were performed: in 
vitro cytotoxicity, in vivo acute systemic toxicity, in vivo 
oral irritation potential, in vitro pyrogenic reaction, and 
bioburden.
MATERIALS AND METHODS
Samples
Samples of bovine cancellous bone were processed 
according to a protocol developed at the Osaka University, 
Japan16 with modifications to decrease fat content, to 
improve purification of the bone graft, and by use of 
chemical reagents capable of inactivating viruses17,18 and 
possibly prions.19,20 The modifications were as follows: (1) 
the time of graft exposure to chloroform and methanol was 
increased to approximately 25 days; (2) grafts were washed 
using an ultrasonic washer to optimize removal of organic 
residues, (3) immersed in hydrogen peroxide for 1h (10, 20 
and 30 volumes), and (4) plunged into sodium hypochlorite. 
Finally, (5) the bones were cut in different shapes and 
granulations, were lyophilized, packed and sterilized by 
gamma radiation. 
The 30 x 20 x 10 mm graft samples were sent to the 
laboratory in double packages made of surgical paper and 
PVC film, containing a chemical radiation dosimeter, and 
only those samples selected to determine bioburden were 
sent to the laboratory before sterilization.
The tests described below were performed by outside 
independent laboratories that also perform biologic, 
microbiologic physical and chemical tests for the 
pharmaceutical, medical and hospital industries. These 
laboratories have nationally and internationally Good 
Laboratory Practices Accreditation and are approved by the 
Brazilian Network Laboratories for Health Analysis (Rede 
Brasileira de Laboratórios Analíticos em Saúde - REBLAS) 
to perform biologic and microbiologic tests. The tests were 
performed at three distinct different laboratories in São 
Paulo, SP Brazil.
In vitro evaluation of cytotoxicity
Cell culture: The NCTC Clone 929 lines of mouse 
fibroblast cells (ATCC CCL-1) were used. Cells were grown 
in minimal Eagle medium supplemented with 10% fetal 
bovine serum (MEM + 10% FBS). Cells were maintained 
at 36oC and dispersed using 0.2% trypsin and 0.02% EDTA 
(TE). After dispersion, cells were resuspended in MEM and 
placed in bottles as control cells and on Petry dishes for agar 
diffusion.21,22
Three test samples containing processed and lyophilized 
bovine cancellous bones in a solid, liquid or powder state 
underwent extraction, which was performed with saline or 
cottonseed oil at 37oC for 24h and at 50oC for 72h. 
A negative control group was composed of nontoxic 
filter paper disks 0.5 cm in diameter, and a positive control 
group was composed of toxic latex fragments measuring 0.5 
x 0.5 cm.
Agar diffusion: The NCTC L929 cells lines were grown 
as described above, seeded on Petri dishes at a concentration 
of about 3 x 105 cells/ml, and were incubated for 48h at 37oC 
in a 5% CO2 humidified incubator to form a monolayer. The 
liquid culture medium was replaced with a solid medium 
composed of equal parts of double-concentrated MEM 
medium and BBL agar (BD) containing 0.1% neutral red 
vital stain (USP XXIII/2005, ISO 10993-5). The solid 
samples were placed directly on the solid agar medium; the 
liquid samples were poured on nontoxic filter paper disks 
and placed on the medium; and the powder samples were 
placed in a cylinder fixed above the medium. The dishes 
were incubated again for 24h. The samples were evaluated 
macro- and microscopically, and cytotoxicity was confirmed 
when a halo was found under or around the test sample. 
Halo diameters were measured, in quadruplicate and a mean 
value was calculated and subtracted from the diameter of 
the nontoxic filter paper disks used to soak the samples to 
obtain the zone index (ZI), which is the unstained area by 
the vital stain. ZIs were scored from zero to four, where zero 
corresponds to no halo under or around the sample, and four 
corresponds to a halo greater than 1.0 cm around the sample. 
Cytotoxicity values were correlated to the ZI scores of each 
sample, varying from absent to severe cytotoxicity.21,23
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In vivo evaluation of acute systemic toxicity
Animals: Twenty Albino Swiss male mice with a mean 
weight of 20 g divided into two groups were used for this 
study. 
Tests: Different media and administration routes were used 
for each group of ten animals. In group 1, cotton seed oil was 
used as the medium for the intraperitoneal injection, while in 
group 2, non-pyrogenic sterile saline was used for intravenous 
injection. On each group, five animals were considered for 
tests or as controls. The intraperitoneal substrate for injection 
that were produced in an autoclave at 121oC for 1h.
In group 1, animals were intraperitoneally injected with 
1.0 ml /20 g body weight of sterile cotton seed oil (batch no. 
103K0064). Animals in the test subgroup received 1.0 g of 
bone sample per 20.0 ml of cotton seed oil, and the control 
subgroup received only sterile cotton seed oil. 
In group 2, animals were intravenous injected with 
1.0 ml/20 g body weight of non-pyrogenic sterile saline. 
Animals in the test subgroup received 1.0 g of bone sample 
per 20.0 ml of non-pyrogenic sterile saline solution (batch 
no. 060406Ql001), while the control subgroup only received 
non-pyrogenic sterile saline. 
All animals were treated with disposable sterile 
syringes and needles, and were controlled for body weight, 
macroscopic changes, and number of deaths at 4, 24, 48 and 
72h. The animals were kept in special cages in the laboratory 
facility and received mouse chow and water ad libitum, 
specific care, such as light-dark cycles, room temperature 
and noise control, by the veterinarians and biologists 
involved in the study.24
In vivo evaluation of the oral irritation potential
Animals: Twelve Male Cavia porcellus (Guinea pigs) 
(mean weight = 570 g) were used. The animals were kept at 
18 to 21oC at 64% humidity and 12-hour light-dark cycles 
(12LD).
Tests: Two groups of six animals were divided in a test 
group and a show-treated (controls) group. The extract was 
prepared at a concentration of 0.2 g of bone sample per ml 
of deionized water and incubated at 121oC for 1h. 
The extract was applied for 10 consecutive days on the 
oral mucosa of the six animals in the test group. Before 
application, the mucosa of each animal was daily examined 
macroscopically by a distinct technician than that one who 
had applied the extract, and changes if any were recorded. 
Only deionized water was applied to the oral mucosa of, all 
animals in the control group. 
For the final classification of the extract, the criterion of 
the Brazilian Institute of Health Quality Control (Instituto 
Nacional de Controle de Qualidade em Saúde - INCQS) 
was used. The arithmetic means of readings for edema and 
erythema were calculated at 24 and 72h. Thus, an index was 
calculated by the average of four means – two readings per 
day in two reading days. 
In vitro evaluation of pyrogenicity 
The Limulus Amebocyte Lysate (LAL) assay (batch 
no. FL 0842) of 0.125 UE/ml (unit of endotoxin per ml) 
sensitivity was used for qualitative evaluation of endotoxins 
produced by the bone samples if any. A mixture of 0.1 ml 
LAL and 0.1 ml of the extract was prepared in a test tube. 
The mixture was immediately incubated for 1h at 
a controlled temperature of 37oC. After that, the tubes 
were removed and checked for a fixed gel formation that 
did not slide when the tube was positioned upside down. 
This method was based on the chain reaction between the 
bacterial endotoxin and a protein component of LAL, which 
produces an easily identifiable opaque gel. The formation of 
a gel in the bottom of the tube indicated a positive response 
for endotoxin production by the sample, in an amount equal 
to or greater than A lysate of 0.125 UE/ml sensitivity value 
as specified on the reagent label. Since was considered 
negative (<0.125 UE/ml) no gel formation can be observed.
Determination of microbial load (bioburden)
To determine the microbial load before sterilization, the 
extract were labeled, placed in double blister packs and sent 
for analyzes to the three distinct laboratories involved in 
the study. For each of the three samples, a pool of granulate 
samples was prepared and diluted in 0.9% sterile saline at 
a 1:10 ratio. Serial dilutions were plated in tryptic soy agar 
(TSA) and incubated at 35oC for 24-48h to read the total 
aerobic mesophiles. Serial dilutions were also plated in 
Sabouraud agar and incubated at 25oC for 5 days to read the 
total filamentous fungi. At those time points, colonies of 30-
300 colony forming units (CFU/g) were counted.
RESULTS
In vitro evaluation of cytotoxicity potential 
In vitro evaluation of lyophilized bovine cancellous 
bone showed no cytotoxicity potential in 100% of the 
samples. There were no statistically significant differences 
between control groups (nontoxic filter paper disks 0.5 cm 
in diameter) and test group containing sample of lyophilized 
bovine cancellous bone. ZI scores were zero; that is, there 
were no stained areas under or around the samples. There 
804
CLINICS 2008;63(6):801-6Biocompatibility of bovine bone grafts
Galia CR et al.
was, however, a statistically significant difference between 
these groups and the positive control group, which had a ZI 
of 4, indicating a stained area greater than 1.0 cm around the 
sample (Table 1).
In vivo evaluation of acute systemic toxicity 
During the study, all mice in the test subgroup of group 1 
had a mean weight gain of 0.5 g (from 20.7 g to 21.2 g), and 
the animals in the control subgroup had a mean weight gain 
of 0.6 g (from 21.9 g to 22.4 g); In group 2 of intravenous 
injections, animals in the test subgroup had a mean weight 
gain of 0.5 g (from 20.1 g to 20.6 g) and controls had a mean 
weight gain of 0.6 g (from 22.3 g to 22.9g); these differences 
were also not statistically significant. 
No macroscopic abnormalities were noted and there were 
no deaths in either of the subgroups (Table 2 and 3).
In vivo evaluation of the oral irritation potential
No significant changes in weight or general conditions 
were found in the negative control group or in the test group. 
Observations on the test and control groups at 24 and 72h 
showed that none of the Guinea pigs had edema or erythema 
on the oral mucosa.
Evaluation of pyrogenicity 
All samples showed a negative pyrogenic result, since 
lysates were <0.125 UE/ml and no gel formation occurred.
Determination of microbial load (bioburden) 
The tests to determine product bioburden showed 
negative results for microbial growth before sterilization. The 
physical and chemical processing procedure applied to the 
bovine cancellous bone samples resulted in a product free of 
aerobic mesophilic bacteria, filamentous fungi and yeast. 
DISCUSSION
The low availability and inherent risks associated with 
the use of bone autografts and allografts have led several 
researchers to study and develop alternative bone substitutes, 
such as calcium phosphate ceramics and lyophilized animal 
bone grafts. Several products have been developed, and 
processing and production methods have improved.9, 25
 In this study, we used lyophilized bovine bone grafts 
produced by modifying a protocol originally developed by 
Kakiuchi et al.16 at Osaka University, Japan to minimize 
mechanical, physical and chemical changes, to reduce fat 
content, and to increase purity of the bone graft. Therefore, 
for analytical purposes, it is very similar to deep-frozen, 
unprocessed bone allografts.9 Private companies participated 
in improving this technique because of the large scale 
required for industrial production.
Evaluating the biologic safety of a medical product is 
part of the process of risk management and analysis. Tests 
must be selected according to the type of contact that the 
product will have with the host (i.e., superficial, external or 
implantable), the nature of the place in which the product 
will be applied, and the length of contact between the 
product and host.11-13,26
Quantitative or qualitative biocompatibility tests are 
quick and have been simplified, turning into systematic, 
detailed and safe procedures. Analyzis of material properties 
is currently a common practice in the industrial when both, 
Table 3 – Mean weight and number of deaths in group 2
Readings Initial weight (g) Final weight (g) 4h 24h 48h 72h No. deaths
Test group (extract) 20.1 20.6 Zero Zero Zero Zero 0/5
Control group (saline solution) 22.3 22.9 Zero Zero Zero Zero 0/5
Table 2 – Mean initial and final weight in all animals
Readings Initial weight (g) Final weight (g)
Test group 1 (extract) 20.7 21.2
Control group 1 
(cotton sees oil)
21.8 22.4
Test group 2 (extract) 20.1 20.6
Control group 2 
(saline solution)
22.3 22.9
Table 1 – Macroscopic and microscopic zone index of test 
and control groups 
Petry dish readings
No. 1 No. 2 No. 3 No. 4
Samples ZI ZI ZI ZI
Test (bovine bone) 0 0 0 0
Negative control 0 0 0 0
Positive control 4 4 4 4
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adapting new production methods and analyzis of final 
products are considered. In some cases, these tests may 
preclude the performance of other biologic tests.15 
Systemic toxicity studies evaluate potential adverse 
effects of medical products on other tissues and organs other 
than those caused at the initial contact. These tests evaluate 
the effects that any substance released by the implantable 
product may have on the host general health or organs, such 
as liver, heart, kidneys or brain.14 
The ISO 10993-11 norm,14 which is pliable in terms of 
study designs to investigate such effects, has established 
systematic international testing norms that have increased 
the safety of biomedical products. Study protocols should 
be based on classic toxicological evaluations of drugs and 
other chemical substances. However these protocols should 
be modified to evaluate solid components on medical 
products.27 The product tested in our study did not show 
any systemic reaction, confirming its biocompatibility, an 
essential requirement for its use. 
The in vitro cytotoxicity test is a fast, standardized, 
sensitive and low-cost test to determine whether a material 
contains significant amounts of extractable substances that 
may harm the host. The results of our in vitro cytotoxicity 
tests, which prevent the use of experimental animals, showed 
a good correlation with those reported on in vivo studies 
of short-term implants.27 The results of cytotoxicity tests 
showed that the end product did not have any toxic potential 
that might cause reactions in surromding tissues after 
implantation i.e., no toxic substance was released by the 
processed bone, as well as no chemical residue was found at 
significant levels that might cause tissue damage.
The oral mucosa irritation test focused on whether the 
product would cause irritation when in contact with the oral 
mucosa of Guinea pigs, a useful model, to determine changes 
and lesions that may affect the stratified epithelium.28 
The results of our study indicated that the bone product 
under analysis showed no mucosa harm further supporting 
itsbiosafety.
Contamination with bacterial endotoxins (pyrogenic 
substrates) is often associated with fever, but other 
substances released by distinct materials may also cause 
this side effect. 
An evaluation of the pyrogenic potential of a material 
is typically included in biocompatibility studies. Pyrogenic 
reactions due to contamination by endotoxins are closely 
associated with the manufacturing processes, and assessment 
of contamination is part of the routine measures of 
production control of any material.29 This study showed 
that our end product was pyrogen-free, particularly free of 
bacterial endotoxins or other substances that might cause 
fever when released.
The efficiency of a product sterilization depends on the 
type and number of microorganisms (bioburden) found in 
that product. Therefore, knowing the microbial load before 
sterilization helps to determine parameters for sterilization 
and to plan a more adequate and shorter, less intense 
sterilization than when the process is based on an arbitrary 
number of organisms. Implantable products belong to the 
group of medical health products that require control of the 
microbial load acquired during manufacture and handling.30 
A simple method to determine bioburden should be used 
not only for routine examination of end-products before 
sterilization but also to provide manufacturers on important 
data for designing and controlling production processes, 
particularly considering major sources of contamination.31 
Our tests to determine product bioburden showed that our 
product had a very low microbial load and this information 
was consided to define and validate the sterilization process 
to be used in this product. Additionally, the risks associated 
with the original characteristics of the product and its 
microbial load, the selection of an appropriate sterilization 
method should also consider the production process, the 
product itself and purpose.32 
After evaluating the results of bioburden tests, a 
minimum irradiation dose was defined for sterilization. 
and by using a pharmaceutical sterilization test, the dose 
of 20 kGy was then validated considering a safety margin 
to irradiate the product.33 Of the microorganisms already 
associated with human bone grafts, all, but anaerobic spores, 
are highly sensitive to gamma radiation. Several reports 
showed that high radiation doses (greater than 25 kGy) 
affect the mechanical properties of bone.34 Therefore, the 
use of lower doses, combined with cleaning and inactivation 
methods or the use of preserving radiation, may safely 
sterilize bone assuring maintenance of functional, chemical 
and structural properties.35,36
CONCLUSIONS 
In vivo and in vitro tests showed that lyophilized bovine 
cancellous bone prepared at a semi-industrial scale according 
to a protocol developed by the authors is a reproducible 
product with excellent biocompatibility. 
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